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Objective: To confirm the safety of a new experimental Tampax
 tampon and applicator compared with that
of a currently marketed Tampax
 tampon and applicator using comprehensive gynecological and micro-
biological assessments.
Methods: A 2-month, single-blind, randomized, crossover study was conducted in which each subject served
as her own control. Safety was evaluated by comparing potential product-related irritation (using colposcopic
examination and subject diary data), assessment of vaginal discharge, vaginal pH, and effects on selected micro-
organisms (yeast, Escherichia coli, Staphylococcus aureus and group B streptococci) obtained by vaginal swab
cultures after normal menstrual use in the experimental and control groups.
Results: In total, 110 women completed the study. There were no significant differences between the groups
that used either the experimental or control tampon with regard to prevalence or mean cell density for the
selected microorganisms. No differences were observed in the incidence or severity of erythema, in abrasion
or ulceration of the cervix, vagina, introitus, vulva or perineum, or in mean vaginal pH and discharge assessments.
Therewereequivalentlowincidencesofreportedsymptomssuchasdiscomfortduringinsertion,wearorremoval,
and a similar low incidence of burning, stinging or itching during use of either the control or experimental tampon.
There was a more favorable overall product rating for the experimental tampon (p = 0.003).
Conclusions: This approach provides a combination of gynecological, microbiological and self-reported (diary
recall) methodologies in order to assess tampon safety during use more thoroughly than has previously been
reported, and it supports a comparable safety profile for the experimental tampon and a currently marketed
tampon.
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Tampons have been used for over 60 years as an
internal method of absorbing menstrual flow. In
the USA, tampons are regulated as a class-II
medical device by the Food and Drug Administra-
tion (FDA), thus requiring FDA approval prior
to marketing. Currently marketed tampons are
composed of absorbents consisting of 100%
cotton, 100% rayon, or blends of cotton and
rayon. They are manufactured with or without
an overwrap, and may be provided with a card-
board or plastic applicator for inserting the tampon
into the vagina. Design and material changes to a
currently marketed product that result in a signifi-
cant change in function, or that may have a poten-
tial effect on safety, must be approved by the FDA.
Therefore it is the responsibility of the tampon
manufacturer to provide performance- and
safety-related data to support the introduction of a
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study was conducted as part of a broader program
which includes safety assessment of tampon raw
materials, in-vitro toxic shock syndrome toxin-1
expression and vaginal microflora analyses1.
The objective of this study was to compare a
new tampon design with that of a tampon that
has an established history of use by millions of
women. Although clinical studies that assess the
effects of tampon wear have been reported since
19422, there are no published studies that combine
gynecological, microbiological and diary recall
methodologies to assess in more detail safety-
relatedendpointsassociatedwithtamponuse.The
methods outlined in this study include evaluation
of the condition of the lower genital tract tissues
by colposcopy, and analysis of the prevalence of
selected microorganisms. Previous experience in
clinical studies indicates that a questionnaire
completed by the subjects after product use effec-
tively detects product-related sensations of
burning, stinging and irritation (unpublished
data). Questionnaires are widely used in medical
surveillance and product evaluation, and have
been found to be a valid and reliable method for
subjective assessment of clinical symptoms3–5.
SUBJECTS AND METHODS
Subjects
Healthy adult volunteers (aged 18–45 years)
who normally used super-absorbency (9–12 g)
tampons and had regular monthly menstrual cycles
were recruited for the study and provided their
signed informed consent. Potential subjects were
evaluated by medical history, physical examina-
tion, and colposcopic and microbiology examina-
tions for assessment of exclusion criteria. Specific
exclusionary provisions included current or recent
antibiotic or anti-inflammatory drug and/or
steroid use, active vaginal or urogenital infection,
and a history of herpes, toxic shock syndrome or
any medical condition that might compromise
immune-system functions. Subjects were eligible
for entry to the study if they were deemed to be
healthy by the principal investigator and if they
met the inclusion criteria.
Study products
Two Tampax (Procter & Gamble Company,
Cincinnati, OH) super-absorbency (9–12 g)
tampon products were examined (Figure 1).
The experimental product was a newly designed
chevron-shaped pad with absorbent material
knitted into the cord at the base of the pad. The
experimental tampon components consisted of
an absorbent pad made of cotton and rayon, a
polyethyleneandpolypropyleneoverwrap,cotton
stitching thread, cotton removal cord and a blue
pearlescent plastic (polyethylene) applicator. The
control product was a currently marketed super-
absorbency Tampax product consisting of a
blended cotton and rayon fiber tampon with
a non-woven rayon overwrap, cotton stitching
threadandremovalcord,andaflushablecardboard
applicator. For women who required back-
up menstrual protection, Always Ultrathin
Maxipads and Alldays pantiliners (Procter &
Gamble) were provided.
Study design
Thisstudyhadarandomized,controlled,crossover
design and ran over two consecutive menstrual
cycles.Subjectsusedtheexperimentaltamponone
month and the control product the other month,
with the order of use (experimental/control or
control/experimental) randomly assigned. The
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Figure 1 Tampon products (prior to compression)
used in the study. (a) Control tampon and applicator;
(b) experimental tampon and applicatortampons were provided in plain coded wrappers.
The number of products worn was left to the
discretion of the subjects, who were instructed
to insert, wear and withdraw the study tampons
as they normally would, but not to wear two
tampons at a time. The study design was approved
by an Institutional Review Board prior to the
beginning of the study.
The study subjects were also randomly assigned
to one of two procedural groups, namely for
microbiology or colposcopy. Study data were
collected at visits 1and 2, either during or follow -
ing the subjects’ menstrual cycles. Each subject
kept a tampon-use diary and completed monthly
comfort and product experience questionnaires.
Table 1 summarizes the schedule of events.
Examinations and laboratory tests
Microbiology assessments
Samples were collected for microbiological
analysis from the randomly assigned microbiology
group subjects during day 3 or 4 of each of their
menstrual cycles (visits 1and 2). Vaginal swab
samples were collected separately from the
introitus and from the fornix near the cervix and
were examined for selected microbial species
(Escherichia coli, yeast species, Staphylococcus aureus
and group B streptococci). E. coli was selected as
an indicator of potential colonization from the
lower gastrointestinal tract. Yeast species, S. aureus
and group B streptococci represent endogenous
flora of potential pathological significance6.
Preweighed sterile Dacron swabs (Copan Italia,
Brescia, Italy) were used for collection, with care
taken to avoid contact with surfaces other than
those designated for sampling. Samples were
collectedandthenimmediatelyplated,refrigerated
and either analyzed on site or transported within
3 hours of collection to an additional laboratory
for analysis. The media and methods used for
isolation and identification were as follows.
Swabs were weighed before sampling and after
sampling but prior to dilution and plating. After
sampling, swabs were immediately placed in 5 ml
of phosphate-buffered saline (PBS), mixed on a
vortex for 10 seconds and plated on media as
described below. The results were expressed as
colony-formingunits(CFUs)pergramofsample.
Colonies growing on mannitol salt agar
(BBL 4321173) were identified by typical colonial
morphologyandGramstainasstaphylococci,with
S. aureus identified by the catalase test and the
Accu-Staph (Carr-Scarborough Microbiologicals,
Inc., Decatur, GA) latex agglutination test for
coagulase positive identification. Colonies of yeast
growing on mycosel agar (BBL 4321847) were
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Procedure
Visit 0
Pre-study
Visit 1
Cycle 1
Visit 2
Cycle 2 (Final)
Consent form
Medical history questionnaire
Screening microbiological samples takena
Screening colposcopic examination and vaginal assessment (all subjects)
Dispense tampons for menstrual use
Tampon diary and monthly comfort questionnaire dispensed
Dispense Always products (if desired)
Group 1
(microbiology sampling)b
Group 2
(colposcopic examination)
All subjects
(vaginal assessment)
Questionnaires completed
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
aExcluson criteria: diagnosis of bacterial vaginosis. Trichomonas, yeast infection, Chlamydia or Neisseria gonorrhoeae;
bSamples taken for
Staphylococcus aureus, group B streptococci, yeast and E. coli
Table 1 Summary schedule of eventsidentifiedbytypicalcolonymorphologyandtested
for germ-tube production. Germ-tube-positive
organisms were identified as Candida albicans.
Germ-tube-negative organisms (if present) were
identified as ‘yeast, not C. albicans,’ and were
speciatedasC.glabrataorC.tropicalisusingtheAPI
20C (bioMérieux Vitek, Hazelwood, MO) test.
Beta-hemolytic colonies growing on neomycin
blood agar (BBL 4321791) were identified by
typical colony morphology and Gram stain as
streptococci, and group B streptococci were
identified by the Christie, Atkins, Munch-
Peterson (CAMP) test. E. coli growing on
MacConkey II agar (BBL 4321172) was identified
by typical colony morphology, Gram stain, indole
production, citrate utilization and the API 20E
(bioMérieux Vitek, Hazelwood, MO) test.
Colposcopy examination
Colposcopic examination was performed on the
randomly assigned colposcopy group subjects
24–48 hours after the use of the last tampon
following each of their two study menstrual cycles
(visits 1and 2). The examination was performed
in accordance with World Health Organization
standards for colposcopic examination using a
Leisegang Model 3-B colposcope (Berlin,
Germany), and included visual examination of
the perineum, vulva, introitus, vaginal walls,
vaginal fornices and cervix7. For each location,
the examiner noted the presence or absence of
ulceration(definedasatearintheepithelium,with
a sharp area of demarcation), abrasion (defined as
partially disrupted epithelium, with a diffuse area
of demarcation) and/or erythema (defined as a
vascular prominence noted on colposcopy, or
obvious redness on gross inspection)7.
Ulceration and abrasion were noted as being
either present or absent, while erythema was rated
on a four-point scale, where 0 = none, 1= mild,
2 = moderate and 3 = severe.
Gynecological assessment
Vaginal pH and vaginal discharge were assessed at
the subjects’ regular study visits 1and 2. pH was
measured using pH strips designed for measuring
in the range 3.6–6.1(JT Baker, Phillipsberg, NJ),
and vaginal discharge was assessed as either normal
or abnormal. If it was abnormal, vaginal dis-
charge was assessed for color (white, gray, yellow,
brown, red, green or other) and consistency
(flocculent, menstruating, homogeneous, frothy,
cheesy or other).
Diary and questionnaire assessments
Information on the subjects’ experience with the
two study products was collected using a tampon
use diary and a monthly comfort questionnaire,
both of which were completed during or follow-
ing each month of testing.
A tampon use diary sheet was completed for
eachstudyproductusedandwasreturnedmonthly
following each period. Subjects were instructed
to record the time of insertion and removal of
each tampon, and to note any menstrual or
vaginal symptoms (burning, stinging or itching
sensation, cramping, tampon slipping down or
out, or feeling that it was not properly in place).
Subjects rated the product for overall comfort
(very comfortable/comfortable/neither comfort-
able nor uncomfortable/uncomfortable/very un-
comfortable) and noted any discomfort that was
experienced while inserting, wearing or removing
the tampon.
The monthly comfort questionnaire was
completed at the end of each cycle. Subjects rated
their study product overall (excellent/very
good/good/fair/poor) and rated the comfort level
(very comfortable/comfortable/neither comfort-
able nor uncomfortable/uncomfortable/very un-
comfortable) of their study tampon. Space for
additional comments was also provided.
Statistical analyses
Summary statistics and 95% confidence intervals
were generated for all parameters. All comparisons
were conducted at the 0.05 significance level. To
increase the power of detection of safety concerns
relating to the test tampon, comparisons of certain
parameters (e.g. microbial counts, erythema) were
performed at the one-sided level. Comparisons of
other parameters (e.g. vaginal pH and color assess-
ments) were performed at the two-sided level.
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countsconvertedtolog10CFU/gandvaginalpH),
experimental vs. control means were compared
using the following two-period crossover analysis
method.
For each subject, the treatment difference
(experimental value minus control value) and visit
difference (visit 2 value minus visit 1value) were
derived. The two-sample t-test, with treat-
ment sequence as the factor, was performed on
the treatment differences. If the result (a test for
equal-periodeffect)wasnotstatisticallysignificant,
then the null hypothesis was tested by applying
the paired t test to the treatment differences.
If the result for period effect was statistically
significant, then the null hypothesis was tested by
applying the two-sample t-test (with treatment
sequence as the factor) to the visit differences. If
parametric assumptions were not met, then the
Wilcoxon rank-sum test and signed-rank test
were performed.
For categorical data (e.g. microbiology data
prevalence defined as the percentage of subjects
with detectable CFU values, the percentage
of subjects with erythema, the distributions of
individual erythema scores, the percentage of
subjects with positive abrasion and ulceration
findings, the percentage of subjects with
normal/abnormal vaginal discharge assessments
and distributions of color/consistency), experi-
mental versus control values were analyzed
by means of stratified Cochran–Mantel–Haenszel
tests.
RESULTS
A total of 224 subjects were recruited and
evaluated for inclusion and exclusion criteria. Of
these, 53 subjects were dropped from the study
before product use due to non-compliance with
the protocol, or because they were ineligible
according to the exclusion criteria. Thus a total of
171 subjects entered the product-use phase of
the study. Of the 171 menstruating women who
enrolled in the study and entered the product-use
phase, 141 women completed the study (39
women in the microbiology group and 102
women in the colposcopy group). Of the 39
microbiology subjects who completed visit 2, five
were not evaluable for the statistical analyses with
microbial end points due to non-compliance with
the protocol. Of the 102 colposcopy subjects who
completed visit 2, 26 women were not evaluable
for the statistical analyses of vaginal condition due
to non-compliance with the protocol. No subjects
dropped out because of a product-related adverse
event.
The subjects had an average age of approxi-
mately 34 years (range 19–45 years). Most were
Caucasian (94%), and the remainder were
Hispanic or Asian. There were no statistically
significant differences in tampon wear time
between the control and experimental products
(Table2).Theaverageweartimeforsubjectsinthe
microbiologygroupwas5.1hoursforbothcontrol
andexperimentaltampons.Theaverageweartime
for those in the colposcopy group was 5.4 and 5.5
hours for control and experimental tampons,
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Experimental Control
Parameter Mean Minimum Maximum SE Mean Minimum Maximum SE p-value
Microbiology group (n = 35)
Average WT (hours)
Average daily number
5.1
3.6
2.5
1.0
9.7
10.0
0.25
0.26
5.1
3.8
2.1
1.5
8.4
9.3
0.27
0.24
0.905
a
0.212
a
Colposcopy group (n = 97)
Average WT (hours)
Average daily number
5.5
3.2
2.2
1.3
10.7
8.0
0.16
0.10
5.4
3.1
2.7
1.7
9.6
7.5
0.14
0.09
0.245
b
0.265
a
aTwo-sided p-value based on paired t-test;
bTwo-sided p-value based on two sample t-test on paired data; period effect detected;
SE, standard error
Table 2 Average tampon weartime (WT) and daily number of tampons used per subjectrespectively. Both control and experimental
tampons were worn for ≤ 8.2 hours by the
majority (95%) of subjects (data not shown).
Microbiology results
Microbiology data were compiled and analyzed
for 34 subjects who completed the study in
compliance with the protocol. The prevalence of
microorganisms detected at each sampling site (the
cervix and introitus) for both products is summa-
rized in Table 3. All yeasts present were identified
as C. albicans. The prevalence of all assessed
organisms was statistically similar (p ≥ 0.159) for
the control and experimental legs of the study
(data not shown). Overall, the prevalence of the
examinedorganismswasgenerallylow,thehighest
prevalence being found for group B streptococci
and S. aureus (up to 18% of subjects at either
examined site). E. coli and C. albicans were identi-
fied in 9% and 6% of subjects at the cervix and
introitus, respectively. The mean counts of
examined organisms were similarly low, with
mean log10 counts ranging from 0.1 to 1.1, and no
statistically significant differences (p ≥ 0.50) were
foundinthemeancountsbetweentheexperimen-
tal and control legs at either the cervix or the
introitus for any organism evaluated (data not
shown).
Colposcopy results
Colposcopy results were compiled and analyzed
for 76 subjects who completed the study in
compliancewiththeprotocol.Table4summarizes
the incidence of erythema, abrasion and ulceration
at each individual examined anatomical site and
theoverall(i.e.atanyexaminedsite).Itcanbeseen
that the incidence of erythema was statistically
similar between the experimental and control
study legs (p ≥ 0.197), and ranged from 41% to
99%and36%to100%duringtheexperimentaland
control legs, respectively. The vast majority of
erythema seen at any site was either mild or
moderate (score = 1or 2). Severe erythema was
seeninonlytwosubjects(2.6%)attwosites(cervi-
cal ectopy and vulva) in both the experimental
and control legs, respectively. No severe erythema
was seen in the other four anatomical sites that
were examined (squamous mucosa, upper vagina,
mid/low vagina and introitus) (data not shown).
Similarly, no statistically significant difference
was found in the incidence of abrasion (p ≥ 0.841)
or ulceration (p = 0.921) between experimental
and control product use. No incidence of abrasion
or ulceration was seen at any site while the experi-
mental product was being used. After use of the
control product at visit 1, abrasion was observed in
two subjects at each of two sites (middle/lower
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Experimental Control
Organism and site
Prevalence
n (%) Mean
a SE
Prevalence
n (%) Mean
a SE
Staphylococcus aureus
Cervix
Introitus
3 (9)
3 (9)
6.1
6.1
0.26
0.53
4 (12)
6 (18)
4.5
5.2
0.39
0.42
Yeast – Candida albicans
Cervix
Introitus
1 (3)
2 (6)
3.3
4.4
0.00
0.15
0 (0)
2 (6)
0.0
3.9
0.00
0.22
Group B streptococci
Cervix
Introitus
6 (18)
5 (15)
5.9
6.3
0.39
0.35
6 (18)
6 (18)
5.8
6.4
0.35
0.42
E. coli
Cervix
Introitus
3 (9)
4 (12)
4.6
4.7
0.75
0.33
3 (9)
3 (9)
5.4
5.0
0.43
0.38
aMean cell densities expressed as log10 CFU/g. SE, standard error of the mean
Table 3 Prevalence and cell density of microorganisms in positive casesvagina and upper vagina), and the same two
subjects had ulcerations at the same two sites
(incidence ≤ 3%). No medical follow-up was
necessary in either of these cases. At visit 2, the
results of the colposcopic examination showed
no abrasion or ulceration in these subjects.
Gynecological results
Vaginal pH and discharge data were analyzed for a
smaller number of subjects than the other study
parameters, due to lack of usable data. In total,
vaginal pH was analyzed for 10 microbiology
group subjects and 60 colposcopy group subjects,
and the results are summarized in Table 5. It can
be seen that the mean pH values were very con-
sistent between the experimental and control legs
ineachproceduralgroup,withmeanexperimental
versus control values of 5.4 versus 5.1and 4.8
versus 4.7 for the microbiology and colposcopy
groups, respectively. No statistically significant
differences were found between the two study
legs in either procedural group (microbiology,
p = 0.421; colposcopy, p = 0.857).
Most vaginal discharge was assessed as normal
for both experimental and control products,
namely 97 versus 81% for the 32 microbiology
subjects (p = 0.971) and 96 versus 95% for the 75
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Type of incidence and
genital site
Experimental Control
n
a %
a n
a %
a p-value
b
Erythema (> 0)c
Any site
Cervix
Squamous mucosa
Ectopy
Upper vagina
Mid/low vagina
Introitus
Vulva
75
71
31
58
64
66
68
99
94
41
77
84
87
90
76
71
27
63
65
72
74
100
93
36
83
86
95
97
0.841
0.500
0.197
0.841
0.591
0.958
0.983
Presence of abrasion
Any site
Cervix
Squamous mucosa
Ectopy
Upper vagina
Mid/low vagina
Introitus
Vulva
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
2
1
0
0
3
0
0
3
1
0
0
0.921
—
—
0.921
0.841
—
—
Presence of ulceration
Any site
Cervix
Squamous mucosa
Ectopy
Upper vagina
Mid/low vagina
Introitus
Vulva
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
2
2
0
0
3
0
0
3
3
0
0
0.921
—
—
0.921
0.921
—
—
an and % = number and percentage, respectively, of subjects with incidence at genital sampling site;
bone-sided p-values based on stratified
Cochrane–Mantel–Haenszel test;
cdata for subjects with any erythema (i.e. erythema score > 0, where 0 = none, 1 = mild, 2 = moderate
and 3 = severe)
Table 4 Erythema, abrasion and ulceration incidence in colposcopy procedural group (n = 76)colposcopy subjects (p = 0.673), respectively. For
those microbiology subjects who were rated as
‘non-normal,’ the only color noted was ‘red’ and
the only consistency noted was ‘menstruating’
(microbiology subjects were examined during
their menstrual periods). Among the colposcopy
subjects with discharge who were rated as
‘non-normal,’ the consistency assessment was
either ‘menstruating’ or ‘homogenous,’ and was
not significantly different between the experi-
mental and control legs (p = 0.549). No color
assessments were noted for colposcopy group
cases with non-normal vaginal discharge.
Diary and questionnaire results
Product acceptance was assessed using a monthly
product questionnaire and tampon use diary. The
questionnaire and diary data indicated consistently
positive assessments of both study tampons,
although there was a more favorable overall
product rating for the experimental tampon
(p = 0.003) (data not shown). When assessing the
experimental tampon, 92% of colposcopy subjects
and 91% of microbiology subjects rated it as
good to excellent overall, with positive to neutral
comfort ratings given by 94% of the colposcopy
subjects and 100% of the microbiology subjects.
These results are similar to the 88 and 89% of
good to excellent overall ratings and 94 and 95%
of positive to neutral comfort ratings given to the
control tampon in the colposcopy and micro-
biology groups, respectively. There were equiva-
lent (p ≥ 0.982) low incidences of reported
menstrual-related symptoms such as discomfort
during insertion, wear or removal (≤ 12.4%), and
vaginal symptoms such as burning, stinging or
itching (≤ 1.7%).
DISCUSSION
Menstrualtamponshavebeenwidelymarketedfor
over 60 years and are currently used by up to
50% of menstruating women in industrialized
countries8. In addition to this long history of use
and acceptance, the safety of tampons has been
documented over the years in clinical studies9–11.
Althoughtheparametersexaminedinthesestudies
have varied, they have generally included assess-
ment of potential changes in the microflora of
the vagina and/or possible mechanical irritation
effects associated with tampon use. This report is
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Parameter Experimental Control p-value
Vaginal pH
Microbiology group (n = 10)a
Mean (SE)
Colposcopy group (n = 60)a
Mean (SE)
5.4 (0.24)
4.8 (0.10)
5.1 (0.19)
4.7 (0.09)
0.421c
0.857
c
Vaginal discharge
Microbiology group (n = 32)a
Normal: n (%)b
Abnormal: n (%)b
Colposcopy group (n = 75)
a
Normal: n (%)b
Abnormal: n (%)b
31 (97%)
1 (3%)
72 (96%)
3 (4%)
26 (81%)
6 (19%)
71 (95%)
4 (5%)
0.971d
0.673d
Vaginal discharge consistency
Colposcopy group (n = 75)a
Menstruating: n (%)b
Homogeneous: n (%)
b
2 (3%)
1 (1%)
4 (5%)
0 (0%)
0.549e
an = number of evaluable subjects for whom experimental and control data are not missing;
bn = number of subjects with category of
response;
cTwo-sided p-value for vaginal pH based on paired t-test;
dOne-sided p-value for abnormal vaginal discharge based on stratified
Cochrane–Mantel–Haenszel (CMH) test;
eTwo-sided p-value for consistency based on stratified CMH general association test; SE, standard
error of the mean
Table 5 Gynecological assessment summary for microbiology and colposcopy groupsthefirstofitskindtocombinegynecologic,micro-
biological and diary assessment methods to evalu-
ate the safety of tampon use.
More recently, as new tampons have been
developed, studies have been conducted to com-
pare the safety profiles of various tampons, with
comparisons being made between tampons made
of different absorbent materials and/or tampons
with different degrees of absorbency8,12–15. This
was the central purpose of this study, namely
to compare the safety of a currently marketed
tampon (Tampax super-absorbency tampon)
with a newly designed tampon with the same
absorbency capability. As part of an ongoing
research and product development effort, the
present study was designed both to ascertain the
safety-in-use profile of the new tampon and to
contribute to the body of knowledge and under-
standing of vaginal health and tampon use.
Our primary goal was to compare a new
tampon shape, absorbent braid and plastic applica-
tor with those of a tampon with an established
history of use. To achieve this, we designed a
single-blind, crossover, clinical safety-in-use study
in which each woman served as her own control.
In order to ensure a realistic scenario, subjects
were required to be current users of super-
absorbency tampons and were instructed to use
the study products as they would use their normal
menstrual protection. Microbiological and colpo-
scopic examinations were performed, with each
subject assigned to either the microbiological or
colposcopic group. In addition, two gynecological
examinations per subject (including measurement
of vaginal pH and assessment of vaginal discharge)
were performed. Microbiological parameters
included the prevalence and mean counts of four
species (S. aureus, C. albicans, group B streptococci
and E. coli), and colposcopy examination included
assessment of erythema, abrasion and ulceration at
six anatomical sites (perineum, vulva, introitus,
vaginal walls, vaginal fornices and cervix).
The average tampon wear time in this study
(5.1–5.5 hours) is consistent with the results
obtainedfromconsumerteststudiesusingthesame
tampons in which the average tampon wear time
was 5.2 hours for both control and experimental
products (unpublished data).
The crossover comparisons of all microbial
parameters in this study indicated that there were
no statistically significant differences between the
experimental and control tampon. The micro-
biology assessments of 34 subjects indicated a
similar prevalence of the four individual species
assessed. Similarly, mean log10 counts were also
consistent between the two study arms. As such,
these findings with regard to comparison of the
effect of two different designs of tampons using
similar fibers are consistent with previous studies
which have found that tampon use has little effect
on the vaginal microflora9,12–15.
The prevalence figures of S. aureus, E. coli and
Group B streptococci in positive cases (Table 3)
were similar to the values found in the published
literatureontamponusers9,16–19,buttheprevalence
of C. albicans in this study (3–6%) is lower than
previously reported values (11–19%)9,17.
Crossover comparison of visual parameters as
assessed by the colposcopic examination of 76
subjects in this study also revealed no statistically
significant differences in the incidence of lower
genital tract irritation between the two tampons,
as recorded by erythema and subjective data.
Although mild erythema was frequently present,
abrasion or ulceration were rare, and were seen in
only two of the subjects. As in the published litera-
ture, our results showed that erythema or other
minor vaginal irritation is not uncommon, and in
fact has also been shown to occur in women who
use external sanitary protection20. The rare inci-
dence of more serious effects, such as ulceration, is
similarly consistent with other studies of normal
menstrual use of tampons which found ulceration
as an uncommon type of lesion20–22. There have
been few studies that have compared product-
related irritation between different tampons8,a s
most of the published literature has dealt with
ulcerationassociatedwithnon-typicaltamponuse,
includingdailyuseofsuper-absorbentproductsfor
many months23,24. However, our results confirm
those of studies of tampons in normal menstrual
use, which have generally found no significant
differences in irritation between different
tampon fibers or absorbency levels15,20,21.
There were no differences in vaginal pH
between users of the experimental and control
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group. The higher mean pH for the microbiology
group compared with the colposcopy group is
probably due to the different days during the
menstrual cycle when the measurements were
obtained. The microbiology group measurements
were made on either day 3 or day 4 of each
menstrual period, and the colposcopy group
measurements were made 1to 2 days after each
menstrual period. The pH of the vagina is higher
(i.e. less acidic) during menstruation, probably due
to the alkalinity of the blood that is present25,
and our results are consistent with previously
reported values of vaginal pH during and after
menstruation26.
The results of the tampon use diaries and
monthly questionnaires that were used to assess
additional safety-related end points such as
burning, stinging or itching revealed no subjective
evidence of vaginal effects due to use of either
the control or experimental tampon.
In conclusion, the data obtained from this
crossover study demonstrate that normal
menstrual use of the new chevron-shaped
tampon with absorbent braid and plastic applica-
tor is unlikely to have an adverse effect on
vaginal health. The colposcopic, microbiological
and diary records that were used to evaluate
objectively and subjectively vaginal condition
during tampon use provide a sensitive and
thorough method for comparing the safety of
different tampon designs.
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